CorMedix (CRMD) Goodwill & Intangibles (2019 - 2025)
CorMedix (CRMD) reported Goodwill & Intangibles of $409.1 million for Q4 2025, up 20353.7% on a YoY basis from N/an in Q4 2024, and down 0.57% sequentially from $411.4 million in Q3 2025.
CorMedix (CRMD) Goodwill & Intangibles (2019 - 2025) Analysis & Trends
CorMedix (CRMD) has 4 years of Goodwill & Intangibles data on file, last reported at $409.1 million in Q4 2025.
- For the quarter ending Q4 2025, Goodwill & Intangibles rose 20353.7% year-over-year to $409.1 million; the trailing twelve-month figure through Dec 2025 stood at $409.1 million (up 20353.7% YoY), and the FY2025 full-year result was $409.1 million, up 20353.7% from the prior year.
- Goodwill & Intangibles fell to $409.1 million in Q4 2025, from $411.4 million in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $411.4 million in Q3 2025 to a low of $1.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,011.97 Bn | 67,011.68 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.88 Bn | 467.08 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.20 Bn | 114.96 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.17 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | CorMedix | 4.94 Mn | -150.27 Mn | 107.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 409.07 Mn |
| Sep 30, 2025 | 411.42 Mn |
| Jun 30, 2025 | 1.74 Mn |
| Mar 31, 2025 | 1.79 Mn |
| Dec 31, 2024 | 2.00 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Sep 30, 2020 | 372,454.00 |
| Jun 30, 2020 | 296,574.00 |
| Dec 31, 2019 | 10,081.00 |